These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25870913)

  • 21. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Positive Allosteric Modulator of the Serotonin 5-HT
    García-Cárceles J; Decara JM; Vázquez-Villa H; Rodríguez R; Codesido E; Cruces J; Brea J; Loza MI; Alén F; Botta J; McCormick PJ; Ballesteros JA; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
    J Med Chem; 2017 Dec; 60(23):9575-9584. PubMed ID: 29116785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D
    DiPalma D; Rezvani AH; Willette B; Wells C; Slade S; Hall BJ; Levin ED
    Pharmacol Biochem Behav; 2019 Jan; 176():16-22. PubMed ID: 30419272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
    Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
    Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
    Higgins GA; Silenieks LB; Rossmann A; Rizos Z; Noble K; Soko AD; Fletcher PJ
    Neuropsychopharmacology; 2012 Apr; 37(5):1177-91. PubMed ID: 22189292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The serotonin 5-HT
    Canal CE; Murnane KS
    J Psychopharmacol; 2017 Jan; 31(1):127-143. PubMed ID: 27903793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evidence for combining the 5-HT
    Fletcher PJ; Li Z; Silenieks LB; MacMillan C; DeLannoy I; Higgins GA
    Addict Biol; 2019 May; 24(3):376-387. PubMed ID: 29498158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of Action of Cassiae Semen for Weight Management: A Computational Molecular Docking Study of Serotonin Receptor 5-HT2C.
    Yuen H; Hung A; Yang AWH; Lenon GB
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT
    Higgins GA; Sellers EM
    Prog Brain Res; 2021; 259():229-263. PubMed ID: 33541678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).
    Yang Y; An S; Liu Y; Guo XX; Gao L; Wei JF; Xu TR
    Expert Opin Ther Pat; 2016; 26(1):89-106. PubMed ID: 26609882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.
    Bubar MJ; Cunningham KA
    Curr Top Med Chem; 2006; 6(18):1971-85. PubMed ID: 17017968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT
    Przegaliński E; Witek K; Wydra K; Kotlińska JH; Filip M
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin and drug reward: focus on 5-HT2C receptors.
    Higgins GA; Fletcher PJ
    Eur J Pharmacol; 2003 Nov; 480(1-3):151-62. PubMed ID: 14623358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine/serotonin releasers as medications for stimulant addictions.
    Rothman RB; Blough BE; Baumann MH
    Prog Brain Res; 2008; 172():385-406. PubMed ID: 18772043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonergic anti-obesity agents: past experience and future prospects.
    Halford JC; Boyland EJ; Lawton CL; Blundell JE; Harrold JA
    Drugs; 2011 Dec; 71(17):2247-55. PubMed ID: 22085383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats.
    Fletcher PJ; Li Z; Ji X; Higgins GA; Funk D; Lê AD
    Neuropharmacology; 2022 Sep; 215():109150. PubMed ID: 35644487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
    Gannon BM; Sulima A; Rice KC; Collins GT
    J Pharmacol Exp Ther; 2018 Mar; 364(2):359-366. PubMed ID: 29217539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.